- FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- Wechsel in der erweiterten Konzernleitung von Roche
- Changes to the Roche Enlarged Corporate Executive Committee
- Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
- FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
- Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
More ▼
Key statistics
As of last trade Roche Holding AG (ROG:SWX) traded at 228.60, 7.37% above its 52-week low of 212.90, set on May 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 228.30 |
---|---|
High | 229.50 |
Low | 227.30 |
Bid | 228.50 |
Offer | 228.60 |
Previous close | 228.80 |
Average volume | 1.46m |
---|---|
Shares outstanding | 809.25m |
Free float | 731.55m |
P/E (TTM) | 16.00 |
Market cap | 187.63bn CHF |
EPS (TTM) | 14.30 CHF |
Annual div (ADY) | 9.60 CHF |
---|---|
Annual div yield (ADY) | 4.18% |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 15 minutes, as of May 29 2024 10:30 BST.
More ▼